Axogen (AXGN) vs CeriBell (CBLL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Axogen (AXGN) has outperformed CeriBell (CBLL) over the past year, gaining 107.5% versus a gain of 79.5%. Axogen is the larger company by market cap ($3.33 billion vs $1.06 billion), about 3.1 times the size, while CeriBell is growing revenue faster (+36.1% vs +20.2%). Axogen converts more of its revenue into profit, with a net margin of -7.0% versus -60.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXGN | CBLL |
|---|---|---|
| Share price | $55.75 | $27.39 |
| Market cap | $3.33B | $1.06B |
| 1-day change | -1.06% | +6.37% |
| YTD return | +70.33% | +24.90% |
| 1-year return | +107.48% | +79.49% |
| 5-year return | +481.33% | — |
| Forward P/E | 79.03 | — |
| EPS (TTM) | $-0.63 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $225.21M | $89.06M |
| Revenue growth (YoY) | +20.21% | +36.09% |
| Net income (latest FY) | $-15.70M | $-53.41M |
| Gross margin | 74.31% | 87.89% |
| Operating margin | -3.49% | -65.57% |
| Net margin | -6.97% | -59.97% |
| 52-week high | $59.72 | $28.89 |
| 52-week low | $26.92 | $14.87 |
| Distance from 52-week high | -6.65% | -5.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +6.31% | +15.26% |
| Average volume | 1.57M | 452.64K |
| Shares outstanding | 59.73M | 38.84M |
| Employees | 622 | 327 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Axogen is about 3.1 times larger than CeriBell by market value ($3.33B vs $1.06B).
- AXGN has outperformed CBLL by 28.0 percentage points over the past year.
- Axogen is more profitable, keeping -7.0 cents of every revenue dollar as net income versus -60.0 cents for CeriBell.
- CeriBell grew revenue faster in its latest fiscal year (+36.09% vs +20.21%).
About Axogen
AXGN stock →Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees
About CeriBell
CBLL stock →CeriBell, Inc. operates as a medical technology company in the United States.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 327 employees
AXGN vs CBLL FAQ
Which is bigger, Axogen or CeriBell?
Axogen (AXGN) is larger, with a market capitalization of $3.33B compared with $1.06B for CeriBell (CBLL).
Which stock has performed better over the past year, AXGN or CBLL?
AXGN returned +107.48% over the past 12 months, compared with +79.49% for CBLL (price return, excluding dividends). Past performance does not predict future results.
Are Axogen and CeriBell in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.